Related Experiment Video
Updated: May 4, 2026
05:14
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
1.7K
Complement inhibitors for age-related macular degeneration
Michael A Williams1, Gareth J McKay, Usha Chakravarthy
1Medical Ophthalmology, Eye and Ear Clinic, Royal Victoria Hospital, Grosvenor Road, Belfast, Northern Ireland, UK, BT12 6BA.
The Cochrane Database of Systematic Reviews
|January 17, 2014
Summary
No clinical trials currently exist to evaluate complement inhibitors for age-related macular degeneration (AMD). Further research is needed to determine the safety and efficacy of these potential AMD treatments.
Area of Science:
- Ophthalmology
- Immunology
Background:
- Age-related macular degeneration (AMD) is a prevalent condition with increasing incidence in aging populations.
- The complement cascade, a key immune pathway, is implicated in AMD pathogenesis.
- Complement overactivity presents a logical therapeutic target for AMD treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of complement inhibitors for preventing or treating advanced AMD.
Main Methods:
- Comprehensive literature search of multiple databases including CENTRAL, MEDLINE, EMBASE, AMED, LILACS, OpenGrey, Web of Science, and clinical trial registries.
- Searches were conducted without date or language restrictions, with the last search on November 21, 2013.
- Included randomized controlled trials (RCTs) investigating complement cascade inhibition for advanced AMD prevention or treatment.
Main Results:
- Screening of 317 references identified no published RCTs meeting the inclusion criteria.
- Two ongoing studies (one Phase I, one Phase II) were identified.
Conclusions:
- Insufficient evidence currently exists to recommend complement inhibitors for AMD prevention or treatment.
- Anticipation remains for results from ongoing clinical trials to inform future recommendations.
Related Concept Videos
01:27Diabetic Retinopathy
55
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
55
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:28Angle Closure Glaucoma: Treatment
1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
01:22iPS Cell Differentiation
2.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.2K
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
861
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
861